Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Two ends against the middle

Although Chiron Corp.'s acquisition of Sagres Discovery Inc. doesn't remedy its thin clinical pipeline in cancer, CHIR thinks the deal lays the foundation for a renewable internal source of oncology compounds. In addition, Sagres' approach to target discovery is opposite that of CHIR and other

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE